<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696785</url>
  </required_header>
  <id_info>
    <org_study_id>16178</org_study_id>
    <secondary_id>I1F-MC-RHBV</secondary_id>
    <secondary_id>2015-003932-11</secondary_id>
    <nct_id>NCT02696785</nct_id>
  </id_info>
  <brief_title>A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis</brief_title>
  <acronym>COAST-V</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and efficacy of the study drug known
      as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive
      participants with radiographic axial spondyloarthritis (rad-axSpA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2016</start_date>
  <completion_date type="Actual">October 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS40 is defined as improvement from baseline of greater than or equal to (&gt;=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains.
Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active).
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).
Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function.
Inflammation based on Q5 &amp; Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity &amp; duration of stiffness): Score ranges from &quot;0&quot; (none) and &quot;10&quot; (very severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ASAS20 Response</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain.
Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active).
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).
Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function.
Inflammation based on Q5 &amp; Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity &amp; duration of stiffness): Score ranges from &quot;0&quot; (none) and &quot;10&quot; (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following:
Total back pain
Patient global
Peripheral pain/swelling
Duration of morning stiffness
CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm.
Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response</measure>
    <time_frame>Week 16</time_frame>
    <description>The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem).
BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ASDAS Inactive Disease</measure>
    <time_frame>Week 16</time_frame>
    <description>ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following:
Total back pain
Patient global
Peripheral pain/swelling
Duration of morning stiffness
CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of &lt;1.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema [less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.
Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ASAS Health Index (ASAS HI)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either &quot;I agree&quot; (score of 1) or &quot;I do not agree&quot; (score of 0). A score of &quot;1&quot; is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA.
Lateral spinal flexion
Tragus-to-wall distance
Lumbar flexion (modified Schrober)
Maximal intermalleolar distance
Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chest Expansion</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Occiput to Wall Distance</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of &quot;0&quot; for no activity or &quot;1&quot; for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SPARCC Enthesitis Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of &quot;0&quot; for no activity or &quot;1&quot; for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful).
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anterior Uveitis or Uveitis Flares</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine&quot;. Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = &quot;no days&quot; to 5 = &quot;22-30 days.&quot; The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, &amp; the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti Ixekizumab Antibodies</measure>
    <time_frame>Week 16</time_frame>
    <description>A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a &gt;= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of &gt;= 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. &quot;sum of all joints checked to be swollen&quot; divided by &quot;number of evaluable joints&quot; and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen).
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">341</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Q2W Ixekizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.
Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q4W Ixekizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.
Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double Blind Period: Placebo given SC Q2W to week 14.
Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.
Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Q2W Ixekizumab</arm_group_label>
    <arm_group_label>Q4W Ixekizumab</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are ambulatory.

          -  Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined
             radiographically according to the modified New York criteria.

          -  Participants have a history of back pain ≥3 months with age at onset &lt;45 years.

          -  In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
             drugs (for duration 4 weeks) or cannot tolerate NSAIDS.

          -  If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.

          -  Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have total ankylosis of the spine.

          -  Have received any prior, or are currently receiving, treatment with biologics, tumor
             necrosis factor inhibitors or other immunomodulatory agents.

          -  Have recently received a live vaccine within 12 weeks or have had a vaccination with
             Bacillus Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis Research, PLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Access Research - Huntington Beach</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Assoc. &amp; Osteoporosis Ctr of Colorado Springs, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Rheumatology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arthritis &amp; Osteoporosis</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD, PA</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates MD, PA</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Consultants</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Institute</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanahan Rheumatology &amp; Immunotherapy</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Articularis Healthcare Group, INC dba Columbia Arthritis Ctr</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Health Science Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest Rheumatology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brno</city>
        <zip>611 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Hyōgo</city>
        <zip>366 8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gwangjin-gu</city>
        <zip>05080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrialguide.com/en-US/studies/axial-spondyloarthritis%20(ankylosing%20spondylitis)/RHBV#?postal=</url>
    <description>Click here for more information about this study: A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>October 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <disposition_first_submitted>June 4, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 4, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 8, 2018</disposition_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing Spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02696785/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02696785/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Blinded treatment period (Week 0 to Week 16), followed by extended treatment period (Week 16 to Week 52), followed by post treatment period for a maximum of 24 weeks.
Washout period occurred for only Adalimumab group for 6 weeks (Week 14 to Week 20).</recruitment_details>
      <pre_assignment_details>Participants who completed study were eligible to enroll into a long-term study (Study I1F-MC-RHBY [RHBY]) for up to 2 additional years. Participants that do not enroll into study RHBY will complete the Post-Treatment Follow-Up Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PBO/IXE</title>
          <description>Blinded Treatment Period: Participants received placebo every two weeks by subcutaneous injection.
Extended Treatment Period: Participants received starting dose of 160mg Ixekizumab at week 16 followed by 80mg Ixekizumab either every two weeks (Q2W) or every four weeks (Q4W) by subcutaneous (SC) injection during extended treatment period.
Participants did not receive any intervention during Follow-up period.</description>
        </group>
        <group group_id="P2">
          <title>ADA/PBO/IXE</title>
          <description>Blinded Treatment Period:Participants received 40mg Adalimumab every two weeks by SC injection.
Washout Period: Participants received placebo for 6 weeks. Extended Treatment Period:Participants received 80mg Ixekizumab either Q2W or Q4W by SC injection during extension treatment period.
Participants did not receive any intervention during Follow-up period.</description>
        </group>
        <group group_id="P3">
          <title>IXE80Q2W/IXE80Q2W</title>
          <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection during blinded &amp; extension treatment period.
Participants did not receive any intervention during Follow-up period.</description>
        </group>
        <group group_id="P4">
          <title>IXE80Q4W/IXE80Q4W</title>
          <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection during blinded &amp; extension treatment period.
Participants did not receive any intervention during Follow-up period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Blinded Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Washout period occurred only for Adalimumab group.</participants>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="0">Washout period occurred only for Adalimumab group.</participants>
                <participants group_id="P4" count="0">Washout period occurred only for Adalimumab group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">Participants who completed study were eligible to enroll RHBY &amp; who didn't enroll entered Follow-Up.</participants>
                <participants group_id="P2" count="0">Participants who completed study were eligible to enroll RHBY &amp; who didn't enroll entered Follow-Up.</participants>
                <participants group_id="P3" count="24">Participants who completed study were eligible to enroll RHBY &amp; who didn't enroll entered Follow-Up.</participants>
                <participants group_id="P4" count="16">Participants who completed study were eligible to enroll RHBY &amp; who didn't enroll entered Follow-Up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>PBO/IXE</title>
          <description>Participants received placebo every two weeks by subcutaneous injection during blinded treatment period and 80mg Ixekizumab either Q2W or Q4W by subcutaneous injection during extension treatment period.</description>
        </group>
        <group group_id="B2">
          <title>ADA/IXE</title>
          <description>Participants received 40mg Adalimumab every two weeks by SC injection during blinded treatment period and 80mg Ixekizumab either Q2W or Q4W by SC injection during extension treatment period.</description>
        </group>
        <group group_id="B3">
          <title>IXE80Q2W/IXE80Q2W</title>
          <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection during blinded &amp; extension treatment period.</description>
        </group>
        <group group_id="B4">
          <title>IXE80Q4W/IXE80Q4W</title>
          <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection during blinded &amp; extension treatment period.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="12.01"/>
                    <measurement group_id="B2" value="41.8" spread="11.44"/>
                    <measurement group_id="B3" value="41.3" spread="11.17"/>
                    <measurement group_id="B4" value="41.0" spread="12.13"/>
                    <measurement group_id="B5" value="41.7" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response</title>
        <description>ASAS40 is defined as improvement from baseline of greater than or equal to (&gt;=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains.
Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active).
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).
Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function.
Inflammation based on Q5 &amp; Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity &amp; duration of stiffness): Score ranges from &quot;0&quot; (none) and &quot;10&quot; (very severe).</description>
        <time_frame>Week 16</time_frame>
        <population>All Randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response</title>
          <description>ASAS40 is defined as improvement from baseline of greater than or equal to (&gt;=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains.
Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active).
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).
Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function.
Inflammation based on Q5 &amp; Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity &amp; duration of stiffness): Score ranges from &quot;0&quot; (none) and &quot;10&quot; (very severe).</description>
          <population>All Randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="48.1"/>
                    <measurement group_id="O4" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall Work Impairment Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>5.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall Work Impairment Score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.20</ci_lower_limit>
            <ci_upper_limit>9.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Overall Work Impairment Score.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.52</ci_lower_limit>
            <ci_upper_limit>10.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of Activity Impairment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-7.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of Activity Impairment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-9.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.5</ci_lower_limit>
            <ci_upper_limit>-3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of Activity Impairment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-8.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ASAS20 Response</title>
        <description>ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain.
Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active).
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).
Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function.
Inflammation based on Q5 &amp; Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity &amp; duration of stiffness): Score ranges from &quot;0&quot; (none) and &quot;10&quot; (very severe).</description>
        <time_frame>Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ASAS20 Response</title>
          <description>ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain.
Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active).
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).
Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function.
Inflammation based on Q5 &amp; Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity &amp; duration of stiffness): Score ranges from &quot;0&quot; (none) and &quot;10&quot; (very severe).</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="58.9"/>
                    <measurement group_id="O3" value="64.2"/>
                    <measurement group_id="O4" value="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>5.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>6.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)</title>
        <description>ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following:
Total back pain
Patient global
Peripheral pain/swelling
Duration of morning stiffness
CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm.
Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)</title>
          <description>ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following:
Total back pain
Patient global
Peripheral pain/swelling
Duration of morning stiffness
CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm.
Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.099"/>
                    <measurement group_id="O2" value="-1.30" spread="0.096"/>
                    <measurement group_id="O3" value="-1.43" spread="0.102"/>
                    <measurement group_id="O4" value="-1.37" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response</title>
        <description>The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem).
BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response</title>
          <description>The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem).
BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="32.2"/>
                    <measurement group_id="O3" value="42.0"/>
                    <measurement group_id="O4" value="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>5.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.82</ci_lower_limit>
            <ci_upper_limit>7.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.91</ci_lower_limit>
            <ci_upper_limit>7.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)</title>
        <description>The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)</title>
          <description>The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="0.215"/>
                    <measurement group_id="O2" value="-2.14" spread="0.209"/>
                    <measurement group_id="O3" value="-2.39" spread="0.222"/>
                    <measurement group_id="O4" value="-2.43" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.299</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.307</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>-0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.304</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ASDAS Inactive Disease</title>
        <description>ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following:
Total back pain
Patient global
Peripheral pain/swelling
Duration of morning stiffness
CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of &lt;1.3.</description>
        <time_frame>Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ASDAS Inactive Disease</title>
          <description>ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following:
Total back pain
Patient global
Peripheral pain/swelling
Duration of morning stiffness
CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of &lt;1.3.</description>
          <population>All randomized participants.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="16.0"/>
                    <measurement group_id="O4" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Logistic</method>
            <param_type>LSMean Difference</param_type>
            <param_value>7.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>34.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>36.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>24.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)</title>
        <description>The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema [less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.
Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline and week 16 Berlin score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)</title>
          <description>The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema [less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.
Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
          <population>All randomized participants with baseline and week 16 Berlin score.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.323"/>
                    <measurement group_id="O2" value="-2.92" spread="0.314"/>
                    <measurement group_id="O3" value="-2.77" spread="0.328"/>
                    <measurement group_id="O4" value="-2.54" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.447</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.450</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.452</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
        <description>The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
          <description>The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6432" spread="0.7530"/>
                    <measurement group_id="O2" value="6.9005" spread="0.7310"/>
                    <measurement group_id="O3" value="7.6952" spread="0.7768"/>
                    <measurement group_id="O4" value="7.9686" spread="0.7665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1229" spread="0.8431"/>
                    <measurement group_id="O2" value="2.5550" spread="0.8225"/>
                    <measurement group_id="O3" value="2.7502" spread="0.8763"/>
                    <measurement group_id="O4" value="2.5696" spread="0.8650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PCS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>3.2574</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0437</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2041</ci_lower_limit>
            <ci_upper_limit>5.3106</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PCS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>4.0520</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0720</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9432</ci_lower_limit>
            <ci_upper_limit>6.1608</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PCS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>4.3254</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0641</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2321</ci_lower_limit>
            <ci_upper_limit>6.4186</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MCS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.4321</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1718</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8732</ci_lower_limit>
            <ci_upper_limit>2.7373</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MCS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.6273</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7387</ci_lower_limit>
            <ci_upper_limit>2.9934</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>MCS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.709</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.4467</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1978</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9097</ci_lower_limit>
            <ci_upper_limit>2.8030</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ASAS Health Index (ASAS HI)</title>
        <description>ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either &quot;I agree&quot; (score of 1) or &quot;I do not agree&quot; (score of 0). A score of &quot;1&quot; is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ASAS Health Index (ASAS HI)</title>
          <description>ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either &quot;I agree&quot; (score of 1) or &quot;I do not agree&quot; (score of 0). A score of &quot;1&quot; is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.300"/>
                    <measurement group_id="O2" value="-2.30" spread="0.292"/>
                    <measurement group_id="O3" value="-2.36" spread="0.311"/>
                    <measurement group_id="O4" value="-2.74" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.416</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.87</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.428</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.95</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.423</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)</title>
        <description>High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)</title>
          <description>High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>Milliragm per Litre (mg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.426" spread="1.9244"/>
                    <measurement group_id="O2" value="-7.202" spread="1.8688"/>
                    <measurement group_id="O3" value="-5.209" spread="1.9803"/>
                    <measurement group_id="O4" value="-6.565" spread="1.9582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-8.628</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6724</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.885</ci_lower_limit>
            <ci_upper_limit>-3.371</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-6.635</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7438</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.033</ci_lower_limit>
            <ci_upper_limit>-1.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-7.991</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.351</ci_lower_limit>
            <ci_upper_limit>-2.631</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)</title>
        <description>The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA.
Lateral spinal flexion
Tragus-to-wall distance
Lumbar flexion (modified Schrober)
Maximal intermalleolar distance
Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)</title>
          <description>The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA.
Lateral spinal flexion
Tragus-to-wall distance
Lumbar flexion (modified Schrober)
Maximal intermalleolar distance
Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.080" spread="0.0826"/>
                    <measurement group_id="O2" value="-0.447" spread="0.0800"/>
                    <measurement group_id="O3" value="-0.502" spread="0.0858"/>
                    <measurement group_id="O4" value="-0.408" spread="0.0840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.367</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.592</ci_lower_limit>
            <ci_upper_limit>-0.142</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.422</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.655</ci_lower_limit>
            <ci_upper_limit>-0.189</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.329</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1167</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.558</ci_lower_limit>
            <ci_upper_limit>-0.099</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chest Expansion</title>
        <description>While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All Randomized Participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chest Expansion</title>
          <description>While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All Randomized Participants.</population>
          <units>Centimeters (cm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.152"/>
                    <measurement group_id="O2" value="0.70" spread="0.148"/>
                    <measurement group_id="O3" value="0.49" spread="0.158"/>
                    <measurement group_id="O4" value="0.67" spread="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.211</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.051</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.219</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.215</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Occiput to Wall Distance</title>
        <description>The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Occiput to Wall Distance</title>
          <description>The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.232"/>
                    <measurement group_id="O2" value="-0.72" spread="0.225"/>
                    <measurement group_id="O3" value="-0.69" spread="0.240"/>
                    <measurement group_id="O4" value="-0.73" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.321</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.330</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.327</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score</title>
        <description>Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline and week 16 SPARCC score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score</title>
          <description>Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
          <population>All randomized participants with baseline and week 16 SPARCC score.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.582"/>
                    <measurement group_id="O2" value="-4.21" spread="0.568"/>
                    <measurement group_id="O3" value="-3.97" spread="0.590"/>
                    <measurement group_id="O4" value="-4.25" spread="0.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-5.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.806</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>-3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-4.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.812</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-5.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.816</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)</title>
        <description>The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of &quot;0&quot; for no activity or &quot;1&quot; for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline MASES score &gt; 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)</title>
          <description>The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of &quot;0&quot; for no activity or &quot;1&quot; for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants with baseline MASES score &gt; 0.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.34"/>
                    <measurement group_id="O2" value="-2.6" spread="0.34"/>
                    <measurement group_id="O3" value="-2.3" spread="0.36"/>
                    <measurement group_id="O4" value="-2.4" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.317</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.683</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SPARCC Enthesitis Score</title>
        <description>The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of &quot;0&quot; for no activity or &quot;1&quot; for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline SPARCC score &gt; 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SPARCC Enthesitis Score</title>
          <description>The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of &quot;0&quot; for no activity or &quot;1&quot; for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants with baseline SPARCC score &gt; 0.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.40"/>
                    <measurement group_id="O2" value="-2.9" spread="0.40"/>
                    <measurement group_id="O3" value="-2.7" spread="0.40"/>
                    <measurement group_id="O4" value="-2.6" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>-0.6</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.255</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.398</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)</title>
        <description>The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful).
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline TJC &gt; 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)</title>
          <description>The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful).
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants with baseline TJC &gt; 0.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.53"/>
                    <measurement group_id="O2" value="-2.2" spread="0.55"/>
                    <measurement group_id="O3" value="-2.5" spread="0.58"/>
                    <measurement group_id="O4" value="-3.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.783</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.550</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anterior Uveitis or Uveitis Flares</title>
        <description>Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.</description>
        <time_frame>Baseline through Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anterior Uveitis or Uveitis Flares</title>
          <description>Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.</description>
          <population>All randomized participants.</population>
          <units>Count of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score</title>
        <description>The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine&quot;. Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score</title>
          <description>The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine&quot;. Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.23"/>
                    <measurement group_id="O2" value="-2.2" spread="0.23"/>
                    <measurement group_id="O3" value="-2.5" spread="0.24"/>
                    <measurement group_id="O4" value="-2.1" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)</title>
        <description>The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = &quot;no days&quot; to 5 = &quot;22-30 days.&quot; The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)</title>
          <description>The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = &quot;no days&quot; to 5 = &quot;22-30 days.&quot; The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance.
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.41"/>
                    <measurement group_id="O2" value="-2.7" spread="0.40"/>
                    <measurement group_id="O3" value="-2.5" spread="0.43"/>
                    <measurement group_id="O4" value="-3.0" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores</title>
        <description>The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores</title>
          <description>The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.</description>
          <population>All randomized participants.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Work Impairment Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.82" spread="3.254"/>
                    <measurement group_id="O2" value="-21.44" spread="2.921"/>
                    <measurement group_id="O3" value="-21.36" spread="3.061"/>
                    <measurement group_id="O4" value="-24.06" spread="3.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Activity Impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="2.28"/>
                    <measurement group_id="O2" value="-21.1" spread="2.22"/>
                    <measurement group_id="O3" value="-23.0" spread="2.35"/>
                    <measurement group_id="O4" value="-23.4" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.989</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.082</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.03</ci_lower_limit>
            <ci_upper_limit>6.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.429</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>2.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.71</ci_lower_limit>
            <ci_upper_limit>8.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-5.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.270</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.92</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score</title>
        <description>ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, &amp; the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Participants in Extended Treatment Period Population Who had NSAID Intake at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Ixekizumab</title>
            <description>Participants received placebo every two weeks during blinded treatment period and starting dose of 160mg Ixekizumab at week 16 followed by 80mg Ixekizumab either Q2W or Q4W extended treatment period by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab/Ixekizumab</title>
            <description>Participants received 40mg Adalimumab every two weeks during blinded treatment period and 80mg Ixekizumab either Q2W or Q4W during extended treatment period by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Ixekizumab Q4W/Ixekizumab Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks during blinded treatment and extension period by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>Ixekizumab 80mg Q2W/Ixekizumab 80mg Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks during blinded treatment and extension period by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score</title>
          <description>ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, &amp; the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.</description>
          <population>Participants in Extended Treatment Period Population Who had NSAID Intake at Baseline.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.28" spread="27.472"/>
                    <measurement group_id="O2" value="-5.91" spread="20.861"/>
                    <measurement group_id="O3" value="-7.62" spread="25.430"/>
                    <measurement group_id="O4" value="-9.91" spread="27.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti Ixekizumab Antibodies</title>
        <description>A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a &gt;= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of &gt;= 1:10.</description>
        <time_frame>Week 16</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti Ixekizumab Antibodies</title>
          <description>A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a &gt;= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of &gt;= 1:10.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)</title>
        <time_frame>Week 16</time_frame>
        <population>All randomized participants who received at least one dose of Ixekizumab.</population>
        <group_list>
          <group group_id="O1">
            <title>IXE80Q4W</title>
            <description>Participants received 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>IXE160/80Q4W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q2W</title>
            <description>Participants received 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE160/80Q2W</title>
            <description>Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)</title>
          <population>All randomized participants who received at least one dose of Ixekizumab.</population>
          <units>microgram per millilitre (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="56"/>
                    <measurement group_id="O2" value="3.88" spread="55"/>
                    <measurement group_id="O3" value="11.6" spread="54"/>
                    <measurement group_id="O4" value="11.3" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)</title>
        <description>The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. &quot;sum of all joints checked to be swollen&quot; divided by &quot;number of evaluable joints&quot; and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen).
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline SJC &gt; 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40mg</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)</title>
          <description>The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. &quot;sum of all joints checked to be swollen&quot; divided by &quot;number of evaluable joints&quot; and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen).
LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.</description>
          <population>All randomized participants with baseline SJC &gt; 0.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.55"/>
                    <measurement group_id="O2" value="-2.7" spread="0.53"/>
                    <measurement group_id="O3" value="-3.6" spread="0.53"/>
                    <measurement group_id="O4" value="-2.7" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)</title>
        <description>MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants with baseline and week 16 SPARCC MRI score for spine.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo every two weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab</title>
            <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
          </group>
          <group group_id="O3">
            <title>IXE80Q4W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
          </group>
          <group group_id="O4">
            <title>IXE80Q2W</title>
            <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)</title>
          <description>MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers.
LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors</description>
          <population>All randomized participants with baseline and week 16 SPARCC MRI score for spine.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="1.147"/>
                    <measurement group_id="O2" value="-11.57" spread="1.113"/>
                    <measurement group_id="O3" value="-11.02" spread="1.160"/>
                    <measurement group_id="O4" value="-9.58" spread="1.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-10.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.588</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>-6.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-9.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.591</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>-6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-8.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.603</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>-4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Upto 76 Weeks</time_frame>
      <desc>All randomized participants who received at least one dose of study drug. There are gender specific adverse events, only occurring in male or female participants. The number of participants exposed has been adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Blinded Treatment</title>
          <description>Participants received placebo every two weeks by subcutaneous injection.</description>
        </group>
        <group group_id="E2">
          <title>Adalimumab 40mg - Blinded Treatment</title>
          <description>Participants received 40mg Adalimumab every two weeks by SC injection.</description>
        </group>
        <group group_id="E3">
          <title>IXE80Q2W - Blinded Treatment</title>
          <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
        </group>
        <group group_id="E4">
          <title>IXE80Q4W - Blinded Treatment</title>
          <description>Participants received starting dose of either 80 milligrams (mg) or 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
        </group>
        <group group_id="E5">
          <title>ADA/PBO - Washout Treatment Period</title>
          <description>Participants received placebo by subcutaneous injection</description>
        </group>
        <group group_id="E6">
          <title>PBO/IXE - Extended Treatment Period</title>
          <description>Participants received starting dose of 160mg Ixekizumab at week 16 followed by 80mg Q2W or 80mg Q4W by subcutaneous injection.</description>
        </group>
        <group group_id="E7">
          <title>ADA/PBO/IXE - Extended Treatment Period</title>
          <description>Participants received 80mg Ixekizumab Q2W or 80mg Q4W by subcutaneous injection.</description>
        </group>
        <group group_id="E8">
          <title>IXE80Q2W/IXE80Q2W - Extended Treatment</title>
          <description>Participants received 80mg Ixekizumab every two weeks by subcutaneous injection.</description>
        </group>
        <group group_id="E9">
          <title>IXE80Q4W/IXE80Q4W - Extended Treatment</title>
          <description>Participants received 80mg Ixekizumab every four weeks by subcutaneous injection.</description>
        </group>
        <group group_id="E10">
          <title>PBO-follow-up Period</title>
          <description>Participants did not receive any intervention.</description>
        </group>
        <group group_id="E11">
          <title>IXE80Q2W-follow-up Period</title>
          <description>Participants did not receive any intervention.</description>
        </group>
        <group group_id="E12">
          <title>IXE80Q4W-follow-up Period</title>
          <description>Participants did not receive any intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="86"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="86"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="33" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" events="37" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="53" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E7" events="24" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E8" events="34" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E6" events="22" subjects_affected="17" subjects_at_risk="86"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E8" events="9" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E9" events="8" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

